Opinions
Alex Ruus
Neptune Tech & Bioresource
NEPT-T
PAST TOP PICK
Dec 06, 2013
$2.900
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
SHORT
For years NEPT was in partnerships where they were extracting Omega-3 oils from krill oil and selling that to consumers. Now they're taking that extraction technology and applying it to the cannabis oil market. He's in a wait-and-see spots. The fundamentals don't back the move up in the stock. He has a small short on this.
(A Top Pick Sept 4/13. Down 14.29%.) Would characterize this as the most exciting stock in his portfolio. Their majority owned subsidiary, Acasti Pharmaceuticals (APO-X) is developing a revolutionary cholesterol/glycerids treatment (CaPre) and have to finance to raise money for a phase 3 trial. Feels both companies are table pounding buys. Stocks have been beaten up on short-term concerns. Expects them both to double or triple in the next year.